These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 1833592)

  • 1. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
    Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
    J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
    Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery.
    Bar-Yosef S; Cozart HB; Phillips-Bute B; Mathew JP; Grocott HP
    Can J Anaesth; 2007 Feb; 54(2):107-13. PubMed ID: 17272249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting.
    Cloyd GM; D'Ambra MN; Akins CW
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):535-8. PubMed ID: 3498862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. A randomized clinical trial.
    London MJ; Franks M; Verrier ED; Merrick SH; Levin J; Mangano DT
    J Thorac Cardiovasc Surg; 1992 Aug; 104(2):284-96. PubMed ID: 1379660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
    Fish KJ; Sarnquist FH; van Steennis C; Mitchell RS; Hilberman M; Jamieson SW; Linet OI; Miller DC
    J Thorac Cardiovasc Surg; 1986 Mar; 91(3):436-42. PubMed ID: 3512919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin resistance after intraoperative platelet-rich plasma harvesting.
    Wickey GS; Keifer JC; Larach DR; Diaz MR; Williams DR
    J Thorac Cardiovasc Surg; 1992 Jun; 103(6):1172-6. PubMed ID: 1597982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost.
    Palatianos GM; Foroulis CN; Vassili MI; Matsouka P; Astras GM; Kantidakis GH; Iliopoulou E; Melissari EN
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):548-54. PubMed ID: 14762367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
    Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
    Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
    Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
    von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study on hemostatic fluctuation during and after cardiopulmonary bypass using hemostatic molecular markers].
    Nakajima H
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Nov; 40(11):1987-97. PubMed ID: 1336789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.